Roche left its financial guidance unchanged – at least for the time being – despite announcing better-than-expected quarterly sales and voicing confidence its pipeline and newly launched drugs will generate revenue and profit growth even as older therapies see their sales eroded by cheaper copies.
The company reported total group sales in the first three months of 2017 rose 4% to CHF12.94bn ($13.02bn) when measured...








